Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
Jessica D. Sun(Threshold Pharmaceuticals (United States)), Charles P. Hart(University of Auckland), Qian Liu(Southeast University), Yan Wang(North Sichuan Medical University), Wen‐Wu Li(VA Palo Alto Health Care System), Dharmendra Ahluwalia(Threshold Pharmaceuticals (United States)), Fanying Meng(Shanghai University), Mark D. Matteucci(University of Auckland), Deepthi Bhupathi(University of Auckland)
PubMed
January 1, 2015
Cited by 27
Related Papers
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
|Journal of Hematology & Oncology|2018|125
Clinical and Translational Oncology
|Clinical & Translational Oncology|2013|124
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome
|Genes Chromosomes and Cancer|2011|107